HPV vaccine cuts cancer outcomes

The HPV vaccine story has moved past “does it work?” and into “how much cancer is it already preventing?” That is the real news now. A global review out on April 30 pulled together real-world studies from multiple countries and found population-level drops not just in HPV infections and genital warts, but in cervical precancer and invasive cervical cancer too. That matters because HPV-linked cancers take years to show up, so seeing the cancer endpoint start to move is the big milestone. (emjreviews.com) ### What changed this week? What changed is the scale of the evidence. The new review in *Expert Review of Vaccines* screened 13,549 records and included 63 studies looking at what happened after HPV vaccination programs rolled out in the real world. It tracked several endpoints at once — HPV infection, CIN2+ cervical precancer, genital warts, invasive cervical cancer, and even some oropharyngeal cancer outcomes. (emjreviews.com) ### Why is cancer the hard endpoint? HPV infection happens early, but cancer usually shows up decades later. So for years, the strongest vaccine evidence came from intermediate markers — fewer infections, fewer warts, fewer high-grade lesions that can turn into cancer. Those markers mattered, but people still wanted proof that the vaccine was changing actual cancer outcomes. That proof is now getting much harder to dismiss. (cochrane.org) ### How big are the declines? They are not subtle. Across the studies in the new review, HPV infections fell by 58% to 100%. CIN2+ fell by 30% to 88%. Genital warts fell by 60% to 90%. Invasive cervical cancer fell by 70% to 88%. The strongest effects showed up where coverage reached at least 70% and where vaccination happened before sexual debut — basically, before exposure to the virus. (emjreviews.com) ### Why does age at vaccination matter so much? Because the HPV vaccine prevents infection — it does not clear an infection somebody already has. That is why routine vaccination is aimed at ages 11 or 12 in the US, with catch-up through age 26. The earlier the vaccine is given, the more likely it is to bl(emjreviews.com) found girls vaccinated before 16 were 80% less likely to develop cervical cancer. (cdc.gov) ### So who is still at risk? A lot of the remaining burden is concentrated in people who missed early vaccination, never got vaccinated, or are not getting screened consistently. That includes adults over 27, where the picture gets more complicated. A new US study in women 27 and older found ongoing new HPV infections well into midlife, with more than 1 in 1(cdc.gov)accination should simply expand to everyone older — the benefit is more selective there — but it does mean risk does not magically end at 26. (news-medical.net) ### Why is access still the catch? Because the biggest gains come from high-coverage programs, and the world does not have those everywhere. The review points out that HPV-related cancer burden remains highest in low- and middle-income countries, where vaccination and screening access are often weaker. Europe is m(news-medical.net)global norm. (emjreviews.com) ### What does this mean for screening and labs? It means the case mix changes. As vaccination pushes down the common vaccine-type infections, the patients who still show up with abnormal screening results are more likely to be older, under-screened, unvaccinated, or infected with a more mixed set of HPV t(emjreviews.com)nation interact over time. (cdc.gov) ### Bottom line? Basically, the HPV vaccine is no longer just preventing a virus on paper. It is visibly shrinking the pipeline that leads from infection to precancer to cancer. The science question is mostly settled. The policy question now is who still is not getting protected — and how fast health systems can close that gap. (emjreviews.com)ted-outcomes-globally/))